Detailed view for LmjF.18.1150

Basic information

TDR Targets ID: 27686
Leishmania major, hypothetical protein, conserved
Source Database / ID:  TriTrypDB  GeneDB

pI: 7.5479 | Length (AA): 360 | MW (Da): 39036 | Paralog Number: 0

Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0

Druggability Group : DG2

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF13920   Zinc finger, C3HC4 type (RING finger)

Gene Ontology

Mouse over links to read term descriptions.
GO:0008270   zinc ion binding  
GO:0005515   protein binding  

Metabolic Pathways

This gene is not mapped to any metabolic pathway in KEGG.

Structural information

Modbase 3D models:

There are 8 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
276 341 1x4j (A) 2 69 27.00 0.0000038 0.89 0.42 0.54
299 351 2bay (A) 2 56 23.00 0 0.77 0.44 -0.85
5 82 4ndj (A) 139 216 5.00 0 0 0.373367 -1.31
288 342 4a49 (A) 374 423 42.00 0.0089 0.94 0.470178 0.5
290 342 5d0m (C) 264 338 28.00 0 1 0.486922 -0.22
293 343 2y43 (A) 18 68 22.00 0 0.7 0.435367 -0.68
295 353 4orh (C) 398 455 26.00 0 0.9 0.521589 -0.49
299 353 2ep4 (A) 77 133 35.00 0.011 0.97 0.485178 0.38

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

Upregulation Percent Ranking Stage Dataset
Upper 60-80% percentile metacyclic. Fernandes MC
Upregulation Percent Ranking Stage Dataset
Mid 40-60% percentile amastigotes. Fernandes MC
Show/Hide expression data references
  • Fernandes MC Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures.

Orthologs

Ortholog group members (OG5_139473)

Species Accession Gene Product
Entamoeba histolytica EHI_091470   hypothetical protein
Leishmania braziliensis LbrM.18.1250   hypothetical protein, conserved
Leishmania donovani LdBPK_181160.1   Zinc finger, C3HC4 type (RING finger), putative
Leishmania infantum LinJ.18.1160   hypothetical protein, conserved
Leishmania major LmjF.18.1150   hypothetical protein, conserved
Leishmania mexicana LmxM.18.1150   hypothetical protein, conserved
Oryza sativa 4325441   Os01g0374900
Trypanosoma brucei gambiense Tbg972.10.15620   hypothetical protein, conserved,predicted zinc finger protein
Trypanosoma brucei Tb927.10.12940   predicted zinc finger protein
Trypanosoma congolense TcIL3000_10_11040   predicted zinc finger protein
Trypanosoma cruzi TcCLB.509805.80   hypothetical protein, conserved
Trypanosoma cruzi TcCLB.503939.120   hypothetical protein, conserved

Essentiality

LmjF.18.1150 has one or more orthologs with essentiality data
Gene/Ortholog Organism Phenotype Source Study
Tb927.10.12940 Trypanosoma brucei significant gain of fitness in bloodstream forms (3 days) alsford
Tb927.10.12940 Trypanosoma brucei significant gain of fitness in bloodstream forms (6 days) alsford
Tb927.10.12940 Trypanosoma brucei significant gain of fitness in procyclic forms alsford
Tb927.10.12940 Trypanosoma brucei no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms alsford
Show/Hide essentiality data references
  • yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database
  • gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84
  • keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection
  • nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource
  • wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170
  • goodall The Essential Genome of Escherichia coli K-12 (Transposon directed high-throughput mutagenesis) Goodall, Emily CA, et al. "The essential genome of Escherichia coli K-12." mBio 9.1 (2018): e02096-17.
  • sidik A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Sidik, Saima M., et al. "A genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genes." Cell 166.6 (2016): 1423-1435.
  • plasmo Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Bushell, Ellen, et al. "Functional profiling of a Plasmodium genome reveals an abundance of essential genes." Cell 170.2 (2017): 260-272.
  • shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan
  • neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs
  • alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924
  • blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930

Phenotypes and Validation (curated)

We have no manually annotated phenotypes for this target. What does this mean? / Care to help?

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

No validation data for this target

Associated compounds / Druggability

Known modulators for this target

No chemical compounds associated to this gene

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
No additional associated druggable targets
Obtained from network model
No druggable targets predicted through repurposing network model

Assayability

Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

No literature references available for this target.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier LmjF.18.1150 (Leishmania major), hypothetical protein, conserved
Title for this comment
Comment